$11.8 million in first quarter 2017 total revenue, including net U.S. Auryxia ® (ferric citrate) product sales of $10.5 million Provides 2017 net U.S Auryxia product sales guidance of $56 to $60 million Target action date of November 6, 2017 set for supplemental new drug application (sNDA) to expand indication of ferric citrate; Expanded indication would leverage reimbursement access, awareness and existing infrastructure From latest 8k http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExNTcwMDUwJkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3 Looking better!